Download PDF
Dtsch Med Wochenschr 2001; 126(Suppl. Gastroenterol. 1): S76-S80
DOI: 10.1055/s-2001-14502
Supplement Gastroenterologie (1)
© Georg Thieme Verlag Stuttgart · New York

Hepatische Enzephalopathie

Hepatic encephalopathyP. Ferenci
  • Universitätsklinik für Innere Medizin IV, Wien
Further Information

Publication History

Publication Date:
11 September 2002 (online)

Also available at
    Permissions and Reprints

Die hepatische Enzephalopathie (HE) ist eine metabolisch induzierte, potenziell reversible Funktionsstörung des Zentralnervensystems im Rahmen von Leberkrankheiten. Im weitesten Sinne schließt sie alle neuropsychiatrischen Syndrome, die bei akuten oder chronischen Lebererkrankungen auftreten können und kausal durch die Leberfunktionsstörung bedingt sind, ein. Die HE umfasst ein breites Spektrum unterschiedlicher klinischer Zustandsbilder. Zahlreiche Synonyme geben meist nur Teilaspekte wieder. Voraussetzung für die Diagnose einer HE ist der Nachweis einer Lebererkrankung, der Nachweis einer Funktionsstörung des zentralen Nervensystems und der sichere Ausschluss einer anderen neurologischen Erkrankung. Während der Nachweis einer Lebererkrankung bzw. die Diagnose der Funktionsstörung des zentralen Nervensystems unproblematisch ist, kann die Abgrenzung zu anderen neurologischen Erkrankungen, die bei Leberkrankheiten auftreten können, schwierig sein.

Literatur

  • 1 Amodio P, Marchetti P, Del Piccolo F. et al . Visual attention in cirrhotic patients.  Hepatology. 1998;  27 1517-1523
    Google Scholar
  • 2 Amodio P, Marchetti P, Del P iccolo F, de Tourtchaninoff M, Varghese P, Zuliani C. et al . Spectral versus visual EEG analysis in mild hepatic encephalopathy.  Clin Neurophysiol. 1999;  110 1334-1344
    Google Scholar
  • 3 Baraldi M, Zeneroli M L. Experimental hepatic encephalopathy - changes in gamma-amino-butyric acid.  Science. 1982;  216 427-431
    Google Scholar
  • 4 Barbaro G, Di Lorenzo G, Soldini M. et al . Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis.  Hepatology. 1998;  28 374-378
    Google Scholar
  • 5 Basile A S, Pandl L, Jaouni T. et al . Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy.  Proc Natl Acad Sci USA. 1990;  87 5263-5267
    Google Scholar
  • 6 Basile A S, Harrison P M, Hughes R D. et al. . Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy.  Hepatology. 1994;  19 112-121
    Google Scholar
  • 7 Bucci L, Palmieri G C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.  Curr-Med Res Opin. 1993;  13 109-118
    Google Scholar
  • 8 Butterworth R F. The astrocytic (»peripheral-type«) benzodiazepine receptor.  Neurochem Int. 2000;  36 411-416
    Google Scholar
  • 9 Cadranel J F, el Younsi M, Pidoux B, Zylberberg P, Benhamou Y, Valla D, Opolon P. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients.  Eur J Gastroenterol Hepatol. 1995;  7 325-329
    Google Scholar
  • 10 Chan H, Hazell A S, Desjardins P, Butterworth R F. Effects of ammonia on glutamate transporter (GLAST) protein and mRNA in cultured rat cortical astrocytes.  Neurochem Int. 2000;  37 243-248
    Google Scholar
  • 11 Conn H O, Leevy C M, Vlahcevic Z R, Rodgers J B, Maddrey W C, Seeff L, Levy L L. Comparison of Lactulose and Neomycin in the Treatment of Chronic Portal-systemic Encephalopathy.  Gastroenterology. 1977;  72 573-583
    Google Scholar
  • 12 Desjardins P, Rao K V, Michalak A, Rose C, Butterworth R F. Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle.  Metab Brain Dis. 1999;  14 273-280
    Google Scholar
  • 13 Egberts E H, Schomerus H, Hamster W, Jürgens P. Branched Chain Amino Acids in the Treatment of Latent Portosystemic Encephalopathy.  Gastroenterology. 1985;  88 887-895
    Google Scholar
  • 14 Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution.  Am J Gastroenterol. 2000;  95 3574-3578
    Google Scholar
  • 15 Ferenci P. Diagnosis and differential diagnosis of hepatic encephalopathy: Implications for the design of clinical studies. Univ. of Newcastle upon Tyne In: Advances in Hepatic encephalopathy and metabolism in liver diseases. CO Record, H Al Mardini (eds) 1997: 267-272
    Google Scholar
  • 16 Ferenci P. Hepatische Enzephalopathie: Ernährung als Ursache oder Therapie?.  Z f Gastroenterologie. 1996;  34 32-34 (Suppl 5)
    Google Scholar
  • 17 Fischer J E, Baldessarini R J. False neurotransmitters and hepatic failure.  ancet. 1971;  ii 75-80
    Google Scholar
  • 18 Grippon P, Le Poncin-Laffite M, Boschat M. et al . Evidence for the role of ammonia in the intracerebral transfer and metabolism of tryptophan.  Hepatology. 1986;  6 682-6686
    Google Scholar
  • 19 Groeneweg M, Gyr K, Amrein R, Scollo-Lavizzari G, Williams R, Yoo J Y, Schalm S W. Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomized, placebo-controlled multicenter trial.  Electroencephalogr Clin Neurophysiol. 1996;  98 29-34
    Google Scholar
  • 20 Horst D, Grace N D, Conn H O. et al . Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy.  Hepatology. 1984;  4 279-287
    Google Scholar
  • 21 Hartmann I J, Groeneweg M, Quero J C, Beijeman S J, de Man R A, Hop W C, Schalm S W. The prognostic significance of subclinical hepatic encephalopathy.  Am J Gastroenterol. 2000;  95 2029-2034
    Google Scholar
  • 22 Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: A clinical manifestation of astrocyte swelling and low-grade cerebral edema?.  J Hepatol. 2000;  32 1035-1038
    Google Scholar
  • 23 Kircheis G, Nilius R, Held C. et al . Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study.  Hepatology. 1997;  25 1351-1360
    Google Scholar
  • 24 Kramer L, Tribl B, Gendo A, Zauner C, Schneider B, Ferenci P, Madl C. Comparison of ammonia partial pressure and total ammonia in hepatic encephalopathy.  Hepatology. 2000;  31 30-34
    Google Scholar
  • 25 Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H. Manganese and chronic hepatic encephalopathy.  Lancet. 1995;  346 270-274
    Google Scholar
  • 26 Kullmann F, Hollerbach S, Holstege A, Schölmerich J. Subclinical hepatic encephalopathy.  J Hepatol. 1995;  22 101-110
    Google Scholar
  • 27 Loguercio C, Abbiati R, Rinaldi M, Romano A, del Vecchio Blanco  C, Coltori M. Long-term effects of enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1 - 2 hepatic encephalopathy.  J Hepatology. 1995;  23 39-46
    Google Scholar
  • 28 Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis.  Hepatology. 1996;  23 1084-1092
    Google Scholar
  • 29 Mendenhall C L, Rouster S, Marshall L, Weesner R. A New Therapy for Portal Systemic Encephalopathy.  Amer J Gastroenterol. 1986;  81 540-543
    Google Scholar
  • 30 Michalak A, Chatauret N, Butterworth R F. Evidence for a serotonin transporter deficit in experimental acute liver failure.  Neurochem Int. 2001;  38 163-168
    Google Scholar
  • 31 Michalak A, Rose C, Butterworth J, Butterworth R F. Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure.  Hepatology. 1996;  24 908-913
    Google Scholar
  • 32 Morgan M Y, Hawley K E. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double blind, randomized trial.  Hepatology. 1987;  7 1278-1284
    Google Scholar
  • 33 Naylor C D, O’Rourkee K, Detsky A S, Baker J P. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A Meta-Analysis.  Gastroenterology. 1989;  97 1033-1042
    Google Scholar
  • 34 Orlandi F, Brunelli E, Benedetti A, Macarri G. Clinical trials of nonabsorbable disaccharide therapy in hepatic encephalopathy. Medi-Ed Press, Bloomington in: Hepatic encephalopathy. Syndromes and Therapies. Conn HO and Bircher J. (eds) 1994: 209-218
    Google Scholar
  • 35 Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Müller M J. ESPEN Guidelines for nutrition in liver disease and transplantation.  Clin Nutrition. 1997;  16 43-55
    Google Scholar
  • 36 Pomier-Layrargues J F, Giguère J, Lavoie J. et al . Flumazenil in cirrhotic patients in hepatic coma:A randomized double-blind placebo-controlled crossover trial.  Hepatology. 1994;  19 32-37
    Google Scholar
  • 37 Quero J C, Hartmann J C, Meulstee J, Hop W C, Schalm S W. The diagnosis of subclinical encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis.  Hepatology. 1996;  24 556-560
    Google Scholar
  • 38 Raabe W. Neuronal effects of ammonia. Elsevier, Amsterdam In: Advances in ammonia metabolism and hepatic encephalopathy. Soeters P, Wilson JHP, Meijer AF, Holm E (eds) 1988: 349-355
    Google Scholar
  • 39 Rees C J, Oppong K, Al Mardini  H, Hudson M, Record C O. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.  Gut. 2000;  47 571-574
    Google Scholar
  • 40 Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy.   Lancet. 1984;  ii 493-495
    Google Scholar
  • 41 Riggio O, Ariosto F. et al . Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy.  Dig Dis Sci. 1991;  36 1204-1208
    Google Scholar
  • 42 Ross B D, Jacobson S, Villamil F, Korula J, Kreis R, Ernst T. et al . Subclinical hepatic encephalopathy.  Radiology. 1994;  193 457-463
    Google Scholar
  • 43 Rudman D, Smith R B, Salam A A. et al . The amino acid content of food.  Am J Clin Nutr. 1973;  26 487-490
    Google Scholar
  • 44 Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis.   J Hepatol. 1993;  19 424-430
    Google Scholar
  • 45 Strauss E, Tramote R, Silva E P, Caly W R, Honain N Z, Maffei R A, de Sa M F. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.  Hepatogastroenterology. 1992;  39 542-545
    Google Scholar
  • 46 Sushma S, Dasarathy S, Tandon R K, Jain S, Gupta S, Bhist M S. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial.  Hepatology. 1992;  16 138-144
    Google Scholar
  • 47 Tarao K, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T. et al . Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy.  Gut. 1990;  31 702-706
    Google Scholar
  • 48 Tromm A, Griga T, Greving I, Hilden H, Huppe D, Schwegler U. et al . Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: Results of a controlled randomized trial.  Hepatogastroenterology. 2000;  47 473-477
    Google Scholar
  • 49 Uribe M, Campollo O, Vargas F. Acidifying enemas (lactitol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: A double-blind randomized clinical trial.  Hepatology. 1987;  7 639-634
    Google Scholar
  • 50 Uribe M, Marquez M A, Gargaramos G. et al . Treatment of chronic portal systemic encephalopathy with lactose in lactase deficient patients.  Dig Dis Sci. 1980;  25 914-928
    Google Scholar
  • 51 Van der Rijt C C, Schalm S W, Meulstee J, Stijnen T. Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study.  Gastroenterol Clin Biol. 1995;  19 572-580
    Google Scholar
  • 52 Van der Rijt C C, Schalm S W, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency.  Gastroenterology. 1991;  100 1114-1118
    Google Scholar
  • 53 Vogels B APM, Maas M AW, Daalhuisen J, Quack G, Chamuleau R AFM. Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats.  Hepatology. 1997;  25 820-827
    Google Scholar
  • 54 Weber F L, Minco D, Fresard K M, Banwell J G. Effects of vegetable diets on nitrogen metabolism in cirrhotic subjects.  Gastroenterology. 1985;  89 538-544
    Google Scholar
  • 55 Weissenborn K, Rückert N, Hecker H, Manns M P. The number connection tests A and B: Interindividual variability and use for the assessment of early hepatic encephalopathy.  J Hepatol. 1998;  28 646-653
    Google Scholar
  • 56 Wiltfang J, Nolte W, Otto M, Wildberg J, Bahn E, Figulla H R. et al . Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy.  Metab Brain Dis. 1999;  14 239-251
    Google Scholar
  • 57 Yurdaydin C, Herneth A, Steindl P, Singer E, Ferenci P. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists.  Eur J Gastroenterol Hepatol. 1996;  8 664-671
    Google Scholar
  • 58 Yurdaydin C, Hörtnagl H, Steindl P, Zimmermann C, Pifl C, Singer E A, Roth E, Ferenci P. Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide induced acute liver failure.  Hepatology. 1990;  12 695-700
    Google Scholar

Univ. Prof. Dr. Peter Ferenci

Universitätsklinik für Innere Medizin IV Klinische Abteilung Gastroenterologie und Hepatologie

Währinger Gürtel 18-20

A-1090 Wien

Email: peter.ferenci@akh-wien.ac.at